Stockreport

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results [Yahoo! Finance]

Lyell Immunopharma, Inc.  (LYEL) 
PDF trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoing Phase 1 trial is ongoing for LYL273, an [Read more]